Search
Picric acid
go.drugbank.com/drugs/DB03651ApprovedUsed as antiseptic, astringent, and stimulant for epitheliazation.
XL784
go.drugbank.com/drugs/DB04991InvestigationalIt is being developed by Exelixis, Inc. … Results of single dose Phase I clinical trials of XL784 administered orally to 96 healthy volunteers have demonstrated that XL784 has attractive safety and pharmacokinetic profiles.
Tallimustine
go.drugbank.com/drugs/DB15466Experimental[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism
Ethyl pyruvate
go.drugbank.com/drugs/DB05869InvestigationalCTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancr...
Efdoralprin alfa
go.drugbank.com/drugs/DB18384Investigational[L54928] It is being investigated as a restorative therapy in adults with AATD emphysema.[L54928]
BRD-810
go.drugbank.com/drugs/DB23607ExperimentalBRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]
Butyrylthiocholine
go.drugbank.com/drugs/DB04250ExperimentalIt is used as a reagent in the determination of butyrylcholinesterase activity. [PubChem]
MB-07803
go.drugbank.com/drugs/DB05053InvestigationalIt is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.